Phase III Teriflunomide adjunct therapy with interferon beta
Phase III Teriflunomide adjunct therapy with interferon beta
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2298 Views
-
Last post by frodo
-
- 0 Replies
- 1317 Views
-
Last post by frodo
-
- 0 Replies
- 1735 Views
-
Last post by NHE
-
- 1 Replies
- 3184 Views
-
Last post by Tif
-
- 2 Replies
- 4413 Views
-
Last post by DIM
-
- 0 Replies
- 2528 Views
-
Last post by NHE
-
- 0 Replies
- 1255 Views
-
Last post by NHE
-
- 2 Replies
- 1920 Views
-
Last post by frodo
-
- 0 Replies
- 11906 Views
-
Last post by NHE